CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胶质母细胞瘤：从病理生理到新型治疗策略
英文原题：Glioblastoma: From Pathophysiology to Novel Therapeutic Approaches.
查看英文原题
Glioblastoma: From Pathophysiology to Novel Therapeutic Approaches.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质母细胞瘤（GBM）是最常见且侵袭性最强的原发性恶性脑肿瘤。尽管采用了当前标准治疗，包括最大程度手术切除、放化疗和肿瘤电场治疗，患者预后仍较差。免疫抑制性肿瘤微环境、药物难以穿越血脑屏障以及强大的耐药机制共同导致治疗失败。表观遗传改变会进一步加剧治疗耐药，增强DNA修复并促进细胞存活通路。分子分型已发现关键预后和预测性生物标志物。基因表达分析划分出具有不同分子特征和治疗脆弱性的GBM亚型，而这些差异也增加了成功实现临床转化的难度。本综述整合GBM的病理生理、诊断和治疗现状，为改善患者结局的未来策略提供参考。
展开英文摘要原文
Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor. Despite the current standard of care therapy, including maximal surgical resection, chemoradiation, and tumor-treating fields, prognosis remains poor. Therapeutic failure is driven by an immunosuppressive tumor microenvironment, poor drug penetration across the blood-brain barrier, and robust resistance mechanisms.
Epigenetic alterations further compound treatment resistance by enhancing DNA repair and promoting survival pathways. Molecular profiling has identified key prognostic and predictive biomarkers. Gene expression analyses have delineated GBM subtypes, each with distinct molecular features and therapeutic vulnerabilities that hinder successful clinical translation. This review integrates the pathophysiological, diagnostic, and therapeutic landscape of GBM to inform of future strategies for improved patient outcomes.
论文信息
- 作者
- Ribeiro A、Fote G、Himstead A、Zheng M、Elliott E、Smith SM、Lou J、Yuen CA
- 单位
- Department of Neurology, Division of Neuro-Oncology, University of California, Irvine, CA 92697, USA.United States
- 文献类型
- 综述
- 期刊
- Biomedicines2025 Aug 12
- 原文标识
- PubMed 40868217 · DOI 10.3390/biomedicines13081963
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →